From selection hits to clinical leads

progress in aptamer discovery

Keith E. Maier, Matthew Levy

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.

Original languageEnglish (US)
Pages (from-to)16014
Number of pages1
JournalMolecular Therapy - Methods and Clinical Development
Volume3
DOIs
StatePublished - Mar 16 2016

Fingerprint

Pharmaceutical Preparations
Social Responsibility
United States Food and Drug Administration
Clinical Trials
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine

Cite this

From selection hits to clinical leads : progress in aptamer discovery. / Maier, Keith E.; Levy, Matthew.

In: Molecular Therapy - Methods and Clinical Development, Vol. 3, 16.03.2016, p. 16014.

Research output: Contribution to journalReview article

@article{fc81b66fb80947ca89d3caf7830d5cdb,
title = "From selection hits to clinical leads: progress in aptamer discovery",
abstract = "Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.",
author = "Maier, {Keith E.} and Matthew Levy",
year = "2016",
month = "3",
day = "16",
doi = "10.1038/mtm.2016.14",
language = "English (US)",
volume = "3",
pages = "16014",
journal = "Molecular Therapy - Methods and Clinical Development",
issn = "2329-0501",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - From selection hits to clinical leads

T2 - progress in aptamer discovery

AU - Maier, Keith E.

AU - Levy, Matthew

PY - 2016/3/16

Y1 - 2016/3/16

N2 - Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.

AB - Aptamers were discovered more than 25 years ago, yet only one has been approved by the US Food and Drug Administration to date. With some noteworthy advances in their chemical design and the enzymes we use to make them, aptamers and aptamer-based therapeutics have seen a resurgence in interest. New aptamer drugs are being approved for clinical evaluation, and it is certain that we will see increasingly more aptamers and aptamer-like drugs in the future. In this review, we will discuss the production of aptamers with an emphasis on the advances and modifications that enabled early aptamers to succeed in clinical trials as well as those that are likely to be important for future generations of these drugs.

UR - http://www.scopus.com/inward/record.url?scp=85015199573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015199573&partnerID=8YFLogxK

U2 - 10.1038/mtm.2016.14

DO - 10.1038/mtm.2016.14

M3 - Review article

VL - 3

SP - 16014

JO - Molecular Therapy - Methods and Clinical Development

JF - Molecular Therapy - Methods and Clinical Development

SN - 2329-0501

ER -